Research programme: ion channel modulators - Icagen, Inc.

Drug Profile

Research programme: ion channel modulators - Icagen, Inc.

Latest Information Update: 08 Dec 2015

Price : $50

At a glance

  • Originator Icagen; University of California at Los Angeles
  • Developer Icagen, Inc.
  • Class
  • Mechanism of Action Nav1.8 voltage-gated sodium channel inhibitors; TRPA1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation; Neuropathic pain; Pain

Most Recent Events

  • 28 Oct 2011 Icagen has been acquired by Pfizer
  • 10 May 2011 Preclinical development is ongoing in USA
  • 11 Feb 2008 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top